Free tool
FAERS Monitor: Qamzova
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217593 or its brand name (Qamzova, Meloxicam). Reports on generic versions are filed under their own applications.
Reports
58,670
Serious
33,720
57% of reports
Hospitalization
14,036
Death reported
3,800
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective6,182
- pain4,886
- fatigue4,833
- arthralgia4,413
- nausea4,028
- headache3,527
- diarrhoea3,424
- dyspnoea2,829
- dizziness2,784
- off label use2,751
- pain in extremity2,683
- malaise2,612
- vomiting2,375
- rheumatoid arthritis2,346
- rash2,341
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 211 |
| 2005 | 311 |
| 2006 | 189 |
| 2007 | 335 |
| 2008 | 525 |
| 2009 | 649 |
| 2010 | 836 |
| 2011 | 1,126 |
| 2012 | 1,711 |
| 2013 | 1,806 |
| 2014 | 2,246 |
| 2015 | 3,478 |
| 2016 | 4,710 |
| 2017 | 4,207 |
| 2018 | 4,905 |
| 2019 | 5,286 |
| 2020 | 5,035 |
| 2021 | 3,923 |
| 2022 | 3,747 |
| 2023 | 3,558 |
| 2024 | 3,586 |
| 2025 | 3,661 |
| 2026 | 2,629 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,995,489 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 2,346 | 7.5 | 7.2 | 13,104 |
| arthralgiaSignal | 4,413 | 3.8 | 3.7 | 9,332 |
| pain in extremitySignal | 2,683 | 3.3 | 3.2 | 4,284 |
| painSignal | 4,886 | 2.9 | 2.8 | 6,066 |
| fatigueSignal | 4,833 | 2.2 | 2.2 | 3,395 |
| malaiseSignal | 2,612 | 2.1 | 2.1 | 1,613 |
| headacheSignal | 3,527 | 2.0 | 2.0 | 1,868 |
| dizzinessSignal | 2,784 | 2.0 | 1.9 | 1,431 |
| rash | 2,341 | 1.9 | 1.9 | 1,065 |
| diarrhoea | 3,424 | 1.9 | 1.8 | 1,513 |
| nausea | 4,028 | 1.8 | 1.8 | 1,563 |
| vomiting | 2,375 | 1.8 | 1.7 | 884 |
| dyspnoea | 2,829 | 1.8 | 1.7 | 1,019 |
| drug ineffective | 6,182 | 1.7 | 1.6 | 1,826 |
| off label use | 2,751 | 1.1 | 1.1 | 41 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.